First Light Asset Management LLC Sells 657,595 Shares of Centessa Pharmaceuticals PLC Sponsored ADR $CNTA

First Light Asset Management LLC decreased its position in shares of Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) by 15.3% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 3,635,816 shares of the company’s stock after selling 657,595 shares during the period. Centessa Pharmaceuticals makes up 8.3% of First Light Asset Management LLC’s holdings, making the stock its 3rd biggest position. First Light Asset Management LLC owned 2.72% of Centessa Pharmaceuticals worth $88,169,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Millennium Management LLC boosted its position in shares of Centessa Pharmaceuticals by 52.9% in the first quarter. Millennium Management LLC now owns 609,188 shares of the company’s stock valued at $8,760,000 after acquiring an additional 210,737 shares during the period. Jane Street Group LLC bought a new position in Centessa Pharmaceuticals during the first quarter worth about $2,176,000. Campbell & CO Investment Adviser LLC acquired a new stake in Centessa Pharmaceuticals in the 2nd quarter worth about $218,000. Geode Capital Management LLC raised its stake in Centessa Pharmaceuticals by 44.7% in the 2nd quarter. Geode Capital Management LLC now owns 87,435 shares of the company’s stock worth $1,149,000 after purchasing an additional 26,994 shares in the last quarter. Finally, Candriam S.C.A. bought a new stake in Centessa Pharmaceuticals in the 2nd quarter valued at about $4,568,000. Institutional investors and hedge funds own 82.01% of the company’s stock.

Centessa Pharmaceuticals Trading Down 3.3%

Shares of Centessa Pharmaceuticals stock opened at $26.33 on Monday. The company has a quick ratio of 10.57, a current ratio of 10.56 and a debt-to-equity ratio of 0.36. Centessa Pharmaceuticals PLC Sponsored ADR has a 12-month low of $9.60 and a 12-month high of $30.58. The company has a market capitalization of $3.85 billion, a price-to-earnings ratio of -14.39 and a beta of 1.54. The firm’s 50-day moving average price is $24.69 and its two-hundred day moving average price is $24.34.

Insider Transactions at Centessa Pharmaceuticals

In related news, insider Iqbal J. Hussain sold 38,951 shares of the stock in a transaction that occurred on Monday, February 2nd. The shares were sold at an average price of $25.15, for a total transaction of $979,617.65. Following the sale, the insider owned 57,645 shares in the company, valued at approximately $1,449,771.75. This trade represents a 40.32% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Gregory M. Weinhoff sold 73,196 shares of Centessa Pharmaceuticals stock in a transaction that occurred on Friday, March 13th. The shares were sold at an average price of $26.33, for a total transaction of $1,927,250.68. Following the completion of the transaction, the insider directly owned 65,925 shares in the company, valued at $1,735,805.25. This trade represents a 52.61% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders sold 233,186 shares of company stock valued at $6,082,890. Company insiders own 7.09% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on the stock. Piper Sandler restated an “overweight” rating on shares of Centessa Pharmaceuticals in a research report on Friday, January 16th. Truist Financial boosted their price target on Centessa Pharmaceuticals from $33.00 to $38.00 and gave the company a “buy” rating in a research note on Thursday, January 29th. Wolfe Research initiated coverage on Centessa Pharmaceuticals in a research report on Tuesday, February 24th. They set an “outperform” rating and a $40.00 price target on the stock. Guggenheim raised their price objective on Centessa Pharmaceuticals from $28.00 to $43.00 and gave the stock a “buy” rating in a research note on Tuesday, November 18th. Finally, TD Cowen reaffirmed a “buy” rating on shares of Centessa Pharmaceuticals in a report on Wednesday, January 14th. Two equities research analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Buy” and an average price target of $39.80.

Centessa Pharmaceuticals Profile

Centessa Pharmaceuticals plc is a global clinical‐stage biopharmaceutical company focused on the discovery and development of innovative therapies across multiple disease areas. The company operates a modular R&D network, bringing together a portfolio of independent, specialist research entities under a single corporate umbrella. This structure is designed to accelerate decision‐making and resource allocation while leveraging deep scientific expertise in each therapeutic domain.

Centessa’s pipeline spans oncology, immunology, neuroscience, cardiovascular and metabolic diseases, as well as rare genetic disorders.